Randall P. Scheri
Duke University
90 Papers
347 Citations
Randall P. Scheri is an academic researcher from Duke University. The author has contributed to research in topics: Medicine & Thyroid cancer. The author has an hindex of 27, co-authored 80 publications. Previous affiliations of Randall P. Scheri include Washington University in St. Louis & Mayo Clinic.
Chat about Author
Papers
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
Mark B. Faries,John F. Thompson,Alistair J. Cochran,Robert H.I. Andtbacka,Nicola Mozzillo,Jonathan S. Zager,Tiina Jahkola,Tawnya L. Bowles,Alessandro Testori,Peter D. Beitsch,Harald J. Hoekstra,Marc Moncrieff,Christian Ingvar,Michel W.J.M. Wouters,Michael S. Sabel,Edward A. Levine,Doreen M. Agnese,Michael A. Henderson,Reinhard Dummer,Carlo Riccardo Rossi,Rogerio I. Neves,Steven D. Trocha,Frances C. Wright,David R. Byrd,Maurice Matter,Eddy Hsueh,Alastair MacKenzie-Ross,Douglas B. Johnson,Patrick Terheyden,Adam C. Berger,Tara L. Huston,Jeffrey D. Wayne,B. Mark Smithers,Heather B. Neuman,Schlomo Schneebaum,Jeffrey E. Gershenwald,Charlotte E. Ariyan,Darius C. Desai,Lisa K. Jacobs,Kelly M. McMasters,Anja Gesierich,Peter Hersey,Steven D. Bines,John M. Kane,Richard J. Barth,Gregory McKinnon,Jeffrey M. Farma,Erwin S. Schultz,Sergi Vidal-Sicart,Richard A. Hoefer,James M. Lewis,Randall P. Scheri,Mark C. Kelley,Omgo E. Nieweg,R. Dirk Noyes,Dave S.B. Hoon,He-Jing Wang,David Elashoff,Robert Elashoff +58 more
TL;DR: Immediate completion lymph‐node dissection increased the rate of regional disease control and provided prognostic information but did not increase melanoma‐specific survival among patients with melanoma and sentinel‐node metastases.
Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients.
Mohamed A. Adam,John Pura,Lin Gu,Michaela A. Dinan,Douglas S. Tyler,Shelby D. Reed,Randall P. Scheri,Sanziana A. Roman,Julie Ann Sosa +8 more
TL;DR: Overall survival was similar in patients undergoing total thyroidectomy versus lobectomy for tumors 1.0–4.0 cm, and it is called into question whether tumor size should be an absolute indication for total Thyroidectomy.
Is There a Minimum Number of Thyroidectomies a Surgeon Should Perform to Optimize Patient Outcomes
Mohamed A. Adam,Samantha M. Thomas,Linda M. Youngwirth,Terry Hyslop,Shelby D. Reed,Randall P. Scheri,Sanziana A. Roman,Julie Ann Sosa +7 more
TL;DR: This is the first study to identify a surgeon volume threshold (>25 total thyroidectomies/y) that is associated with improved patient outcomes and has implications for quality improvement, criteria for referral and reimbursement, and surgical education.
340
Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer
Mohamed Abdelgadir Adam,John Pura,Paolo Goffredo,Michaela A. Dinan,Shelby D. Reed,Randall P. Scheri,Terry Hyslop,Sanziana A. Roman,Julie Ann Sosa +8 more
TL;DR: The results suggest that cervical lymph node metastases are associated with compromised survival in young patients, warranting consideration of revised American Joint Committee on Cancer staging.
330
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Robert I. Haddad,Lindsay Bischoff,Douglas W. Ball,Victor Bernet,E. Blomain,Naifa L. Busaidy,Michael Campbell,Paxton V. Dickson,Quan-Yang Duh,Hormoz Ehya,Whitney S. Goldner,Theresa W Guo,Megan R. Haymart,Shelby A. Holt,Jason P. Hunt,Andrei Iagaru,Fouad Kandeel,Dominick Lamonica,Susan J. Mandel,Stephanie Markovina,Bryan McIver,Christopher D. Raeburn,Rod Rezaee,John A. Ridge,Mara Y. Roth,Randall P. Scheri,Jatin P. Shah,Jennifer A. Sipos,Rebecca S. Sippel,Cord Sturgeon,Thomas N. Wang,Lori J. Wirth,Richard J. Wong,Michael Yeh,Carly J Cassara,Susan Darlow +35 more
TL;DR: The treatment of choice for differentiated thyroid carcinoma is surgery, followed by radioactive iodine ablation (iodine-131) in select patients and thyroxine therapy in most patients, and kinase inhibitors may be appropriate for select patients with recurrent or persistent disease that is not resectable.